Nurse Practitioner Prescriptive Authority for Buprenorphine From DATA 2000 to CARA 2016
Nurse Practitioner Prescriptive Authority for Buprenorphine From DATA 2000 to CARA 2016
复制标题
DOI：
10.1097/jan.0000000000000160
复制
发表时间：
2017-01-01
影响因子：
1.5
通讯作者：
Fogger, Susanne A.
中科院分区：
文献类型：
--
作者：
Fornili, Katherine S.;Fogger, Susanne A.
本“政策观察”专栏的目的是对一项备受期待的立法提供最新情况介绍。该立法于2016年颁布，使得执业护士（以及医师助理）能够在办公室进行阿片类药物治疗（OBOT）并开具丁丙诺啡用于治疗阿片类药物成瘾。首先，将描述2000年《药物成瘾治疗法案》的概况，该法案仅允许医生进行办公室阿片类药物治疗的处方开具。随后将概述2015 - 2016年《成瘾治疗康复促进法案》。最后，将对2016年《综合成瘾康复法案》进行回顾，其中包括有关办公室阿片类药物治疗法规的重要变更信息，这些变更使得执业护士能够开具丁丙诺啡用于治疗阿片类药物成瘾。
The aim of this Policy Watch column is to provide an update on a much anticipated legislation, enacted in 2016, which enabled office-based opioid treatment (OBOT) with buprenorphine prescribing for the treatment of opioid addiction by nurse practitioners (as well as physician assistants). First, an overview of the Drug Addiction Treatment Act of 2000, which only permitted OBOT prescribing by physicians, will be described. It will be followed by a summary of the Recovery Enhancement for Addiction Treatment Act of 2015-2016. Finally, a review of the Comprehensive Addiction Recovery Act of 2016 will be provided, which includes information about important changes to OBOT regulations that enable NP prescribing of buprenorphine for the treatment of opioid addiction.